There is a growing theory that the push for GLP-1 drugs like Ozempic is a precursor to a single-payer healthcare system managed by AI and major insurers like UnitedHealthcare. Proponents suggest these drugs can solve a wide array of chronic conditions, potentially reducing the need for traditional medical interventions.



















